Vernalis Share Discussion Threads

[in despair sybil] 28/10/2009 20:46

DP

unless i'm mistaken the remaining gaps are 75.75 - 77.00 82.00 - 82.50 & 100.00 - 101.00 then 135.00 - 136.00 and plenty more to the upside from what seems like an eternity ago

bestest

IDS

[dpeach] 28/10/2009 10:16

IDS looks like your gaps being closed at the moment... may get pull back though like at 11 ish ;-)

[in despair sybil] 27/10/2009 00:16

wouldn't be too worried by recent price action - the gap from early august has now been filled and we're still in an uptrend. am hoping that we will bounce up strongly from the lower trendline, though there are a couple of more gaps to fill below the current price.

on a positive, can't see any negative newsflow on the short term horizon.

if we get past the recent high of around 110, then i can see the next level being around 125-135 before the next retrace.

bestest

IDS

[dpeach] 26/10/2009 18:09

What was with the mini sell off today though? IMO probably all the recession not over talk and people taking cash in case.

[dpeach] 26/10/2009 12:10

majority buys, back to GSK buy in price @ 87p

[dpeach] 19/10/2009 15:41

Management statement due mid Nov, should be interesting re GSK buys and progress

[lawster] 17/10/2009 18:36

RNS Number : 9790W
Vernalis PLC
06 August 2009

6 August 2009

Vernalis and GlaxoSmithKline enter into a collaboration, option and license agreement over a novel Vernalis oncology programme

Potential deal value in excess of $200 million

Vernalis plc (LSE: VER) today announces that it has entered into an exclusive collaboration, option and license agreement with GlaxoSmithKline relating to a Vernalis research programme against an undisclosed oncology target. During the research phase Vernalis will continue to apply its expertise in Structure Based Drug Design (SBDD) technologies to progress novel development candidates against the target.

The deal is structured as a risk-sharing agreement, with Vernalis responsible for drug discovery activities and GSK for pre-clinical development. Upon IND filing, GSK will have the option to license all collaboration compounds and if this is exercised, will then be responsible for all future development and commercialisation activities.

Under the terms of the deal Vernalis will receive $6 million upon signing (including a $3 million equity subscription by GSK for 2,040,542 new ordinary shares in Vernalis at a subscription price of 87 pence per share) and is eligible to earn up-front and potential milestone payments in excess of $200 million and up to double digit royalties based on worldwide sales of an oncology product. Further milestones and royalties could be earned should products against the target be developed for indications outside of oncology.

"Earlier this year we set ourselves the goal of securing research collaborations to fund a substantial proportion of our research activities. In May we announced a second collaboration with Servier and today we are delighted to announce this licensing agreement with GSK," said Ian Garland, Chief Executive Officer. "The risk sharing structure of today's deal allows us to achieve our research funding goal but to also retain a significant upside from successful development of this novel Vernalis oncology programme. We are delighted to be working alongside GSK and to have another world leading pharmaceutical company endorse our technology and the quality of our work."

-- ends --

[4screws] 17/10/2009 10:00

lawster, where does it show gsk buying 2m at 87p

[lawster] 16/10/2009 20:47

If GSK are willing to buy at 2m at 87p a share they must see something exciting. imo.

[lawster] 16/10/2009 20:44

doesn't look like at all like that to me. How do you come to that conclusion?

[atflores] 14/10/2009 10:03

Currently trending to around 70p by 'December 2010'

[ffp] 09/10/2009 19:26

Never seems to emerge from it though does it?

[lawster] 09/10/2009 19:24

This company has got some great stuff in the pipeline. Reckon we'll be trading higher in no time.

Quiet board though, anyone got any views on this company?

[cestnous] 16/9/2009 13:42

See Fingers analysis at;

[cestnous] 16/9/2009 08:43

And another 8.8% so far this am.

[sjewson] 15/9/2009 21:18

Nice 13% rise today plenty of upside on this one with GSK share price support at 87p

[ffp] 15/9/2009 18:10

Why should that be such good news for the share price to rise that much??

[cestnous] 15/9/2009 16:38

Nice to be in profit (on thin air). Way to go.